BFS
STRO icon

Bare Financial Services’s Sutro Biopharma STRO Stock Holding History

Bare Financial Services’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-55
Closed -$477 – 1692
2025
Q3 		$477 Buy
+55
New +$468 ﹤0.01% 1322

Other funds holding STRO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Bare Financial Services's STRO Position: Q4 2025 in Review

Bare Financial Services sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 55 shares — an estimated $477 sold.

Bare Financial Services first reported a position in STRO in Q3 2025 and held it in 1 quarter. The position peaked at $477 in Q3 2025. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

  • Bare Financial Services reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
  • Bare Financial Services sold 55 Sutro Biopharma shares in Q4 2025, an estimated $477.
  • Bare Financial Services first reported a position in Sutro Biopharma in Q3 2025 and held it in 1 quarter.
  • Bare Financial Services's Sutro Biopharma position peaked at $477 in Q3 2025.
  • 63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on Bare Financial Services's 13F filing for Q4 2025, filed 6 Feb 2026.